COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu
Trial record 2 of 9 for:    CASPIAN

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04660097
Recruitment Status : Not yet recruiting
First Posted : December 9, 2020
Last Update Posted : December 9, 2020
Information provided by (Responsible Party):
Zhaoyanqiu, Henan Cancer Hospital

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : December 4, 2021
Estimated Study Completion Date : November 4, 2022